Olema Initiates Phase 3 OPERA-02 Trial as Q3 Results Highlight Progress

Introduction to OLEMA PHARMACEUTICALS INC

OLEMA PHARMACEUTICALS INC (NASDAQ: OLMA) is a San Francisco–based biotechnology company focused on developing therapies for breast cancer and other solid tumors. Its lead investigational drug, palazestrant (OP-1250), is an oral complete estrogen receptor antagonist currently in Phase 3 development. The pipeline also includes OP-3136, a selective oral KAT6 inhibitor.

Corporate Structure and Expertise

Founded in 2007, Olema employs between 51 and 200 people across research, clinical development, regulatory affairs, and commercial strategy. The company operates from its headquarters in San Francisco, California, and maintains a corporate website at olema.com. Official communications are conducted via “@olema.com” email addresses.

Biotechnology by Louis Reed

Recent Developments and News

• November 10, 2025: Olema reported third quarter 2025 financial and operating results, including the initiation of the Phase 3 OPERA-02 trial of palazestrant plus ribociclib and the presentation of palazestrant combination data at ESMO.
• November 4, 2025: The company announced inducement grants under Nasdaq Listing Rule 5635(c)(4).
• November 3, 2025: Olema confirmed participation in upcoming investor conferences with Guggenheim, UBS, and Jefferies.
• October 30, 2025: A trial-in-progress poster for the Phase 3 OPERA-02 trial was announced to be presented at SABCS 2025.
• October 18, 2025: Olema released new data from the Phase 1b/2 trial of palazestrant plus ribociclib in ER+/HER2- metastatic breast cancer at ESMO.
• October 2, 2025: Inducement grants were issued under Nasdaq Listing Rule 5635(c)(4).

Financial and Strategic Analysis

As of November 17, 2025, OLMA closed at USD 8.40 per share, trading between USD 2.86 and USD 11.54 over the past 52 weeks. The intraday market capitalization was reported at approximately USD 584.98 million, with an average daily volume of approximately 1.19 million shares and a total volume of 11.36 million shares to date in 2025.

In the trailing twelve months, Olema reported a net loss of USD 149.96 million (EPS: –1.76) and a return on equity of –59.22%. As of the most recent reporting period, the balance sheet showed USD 328.96 million in cash and equivalents alongside a debt-to-equity ratio of 1.46%. These resources are intended to support ongoing Phase 3 and Phase 1/2 trials.

Olema’s focus on palazestrant and OP-3136 positions the company to potentially benefit from clinical milestones and various strategic agreements. The success of Phase 3 trials and supportive combination data will be significant.

Market Position and Industry Context

Breast cancer is the second most prevalent cancer globally, with nearly two million new cases annually; approximately 30% of patients may progress to metastatic disease. Olema targets the ER+/HER2- metastatic segment, where complete estrogen receptor antagonists and KAT6 inhibitors are emerging therapeutic classes. Key competitors include companies developing SERDs, CDK4/6 inhibitors, and PI3K/mTOR pathway agents. Olema’s oral palazestrant and its combination regimens may provide distinct opportunities in terms of efficacy and tolerability.

tl;dr

On November 10, 2025, Olema reported Q3 2025 results and launched its Phase 3 OPERA-02 trial of palazestrant plus ribociclib. Enrollment in the Phase 3 OPERA-01 trial is on track for top-line data in H2 2026. The Phase 1/2 OP-3136 program has expanded into combination arms. Olema possesses USD 329 million in cash, and upcoming investor conferences will focus on strategic partnerships and pivotal trial readouts.